The company, which received U.S. regulatory approval earlier this month for new Hepatitis C drug Harvoni, said total product sales for the quarter more than doubled to $5.97 billion from $2.71 billion a year earlier.
Read MoreCan anything slow Gilead down? Analysts say no
Third-quarter Sovaldi sales totaled $2.8 billion, while the prior quarter boasted sales of $3.48 billion. Analysts had anticipated a slowdown as some demand may be waiting for the new treatment, but Tuesday's announcement came in below those tempered expectations. Wall Street analysts, on average, had called for $2.97 billion, according to Deutsche Bank.
"To date approximately 117,000 patients have been treated with Sovaldi and with the introduction of Harvoni—a single tablet regimen for the treatment of HCV-infected individuals which does not require either interferon or ribavirin—many more patients will have the potential to be cured of HCV infection," said John C. Martin, Gilead's Chairman and CEO in the press release accompanying the announcement.
—Reuters contributed to this report.